<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02663323</url>
  </required_header>
  <id_info>
    <org_study_id>MER/EX</org_study_id>
    <nct_id>NCT02663323</nct_id>
  </id_info>
  <brief_title>Pilot Clinical Study of MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System</brief_title>
  <acronym>MeRes-1Extend</acronym>
  <official_title>MeRes-1 Extend: A Prospective, Multinational, Multicenter, Single Arm, Open Label, Pilot Clinical Study of MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System in the Treatment of De-novo Native Coronary Artery Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meril Life Sciences Pvt. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meril Life Sciences Pvt. Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      MeRes-1 Extend study is designed as prospective, multinational, multicentre, single arm, open&#xD;
      label, pilot study to assess the safety and performance of the MeRes100 Sirolimus Eluting&#xD;
      Bioresorbable Vascular Scaffold System (BRS) in subjects with de novo native coronary artery&#xD;
      lesions. 64 subjects will be enrolled from the 8 centers located in Asia Pacific, Europe,&#xD;
      Brazil and South Africa. Primary outcome of study will be Proportion of population reporting&#xD;
      Major Adverse Cardiac Events at 6 months from the day of index Procedure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">February 2, 2016</start_date>
  <completion_date type="Anticipated">July 5, 2020</completion_date>
  <primary_completion_date type="Actual">October 5, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single intervention with MeRes100 Device</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Clinical Endpoint: Proportion of population reporting with Major Adverse Cardiac Event at 6 months from the day of index procedure.</measure>
    <time_frame>6 Month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Safety Endpoint: Proportion of population reporting with Ischemia Driven Major Adverse Cardiac Event (ID MACE) reporting at 6 months (180 days) from the day of index procedure</measure>
    <time_frame>6 Month</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>MeRes100 - BRS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System</intervention_name>
    <description>MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System in the treatment of de-novo coronary artery lesions.</description>
    <arm_group_label>MeRes100 - BRS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        General Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects ≥ 18 years of age&#xD;
&#xD;
          2. Subject is able to sign written Informed Consent Form (ICF)&#xD;
&#xD;
          3. Subjects with symptomatic myocardial ischemia, chronic stable angina&#xD;
&#xD;
          4. The patient has planned intervention of a single de novo lesion in native epicardial&#xD;
             vessel&#xD;
&#xD;
          5. Subject who is an acceptable candidate for Coronary Artery Bypass Grafting (CABG)&#xD;
&#xD;
          6. Subject is not participating in any other clinical investigation/study and agrees not&#xD;
             to participate in any other clinical investigation/study for a period of 3 years&#xD;
             following the index procedure.&#xD;
&#xD;
          7. Subject must agree to undergo all clinical investigation plan-required follow-up&#xD;
             visits, angiograms and OCT as per protocol.&#xD;
&#xD;
        Angiographic Inclusion Criteria:&#xD;
&#xD;
          1. Subject with maximum two treatable de novo lesions located maximum one per native&#xD;
             epicardial vessel located in major artery or branch, with reference vessel diameter&#xD;
             between 2.75, 3.00 and 3.5 mm by on line QCA.&#xD;
&#xD;
          2. Target lesion length ≤ 20 mm.&#xD;
&#xD;
          3. Subjects with Lesion(s), with a visually estimated stenosis of ≥ 50% and &lt; 100% with a&#xD;
             TIMI flow of ≥ 1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General Exclusion Criteria:&#xD;
&#xD;
          1. Subjects unable to provide written informed consent.&#xD;
&#xD;
          2. Pregnant or nursing mother and those who plan pregnancy during the clinical&#xD;
             investigation (female patients must have a negative pregnancy test done within 7 days&#xD;
             prior to the index procedure and effective contraceptive must be used during&#xD;
             participation in this clinical investigation).&#xD;
&#xD;
          3. Subjects with known allergy to Poly-L-Lactide (PLLA), Poly-D,L-Lactide (PDLLA),&#xD;
             Sirolimus (Rapamycin) or its any analog or derivative, clopidogrel, ticlopidine,&#xD;
             prasugrel, contrast media, platinum, ticagrelor and any drug in dual antiplatelet&#xD;
             therapy including aspirin, both heparin and bivalirudin.&#xD;
&#xD;
          4. Subject diagnosed with Acute Myocardial Infarction (AMI) within 7 days preceding the&#xD;
             index procedure, as indicated by elevated levels of cardiac enzymes and/or ST segment&#xD;
             changes in Electro Cardio Gram (ECG).&#xD;
&#xD;
          5. Subject with history of previous revascularization procedures including CABG and&#xD;
             Percutaneous Coronary Intervention (PCI).&#xD;
&#xD;
          6. Subject with vascular aneurysms, cardiac arrhythmias, congestive cardiac failure&#xD;
             having LVEF &lt; 30%, cardiac tamponade.&#xD;
&#xD;
          7. Recipient of an organ in an organ transplant procedure or is on a waiting list for any&#xD;
             organ transplant.&#xD;
&#xD;
          8. Subjects receiving immunosuppression therapy or having known immunosuppressive or&#xD;
             autoimmune disease.&#xD;
&#xD;
          9. Subjects with history of stroke, Cerebro Vascular Accident (CVA) or Transient Ischemic&#xD;
             neurological Attack (TIA). Patients with renal insufficiency where creatinine levels&#xD;
             are more than 1.3 mg/dl, known aplastic anaemia, chronic liver disease, platelet count&#xD;
             &lt;100,000 cells/mm3, a WBC of &lt; 3,000 cells/mm3.&#xD;
&#xD;
         10. Subjects planned for elective surgery within the first 12 months after the procedure&#xD;
             that will require discontinuing dual antiplatelet therapy&#xD;
&#xD;
         11. Subject has a history of bleeding diathesis or coagulatory disease, refuses blood&#xD;
             transfusion, significant gastrointestinal or urinary bleed within the past 12 months.&#xD;
&#xD;
         12. Subject having extensive peripheral vascular disease that precludes safe 6F sheath&#xD;
             insertion.&#xD;
&#xD;
         13. Subject having a history of paradoxical exercise induced vasoconstriction that is&#xD;
             consistent with myocardial bridging in the coronary anatomy.&#xD;
&#xD;
         14. Subjects participating in another clinical investigation.&#xD;
&#xD;
         15. Subjects with short life expectancy such as cancer, Human Immunodeficiency Virus&#xD;
             (HIV)/Acquired Immune Deficiency Syndrome (AIDS), or other co-morbid conditions that&#xD;
             would limit compliance with the follow-up schedule of the study.&#xD;
&#xD;
        Angiographic Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who are non-candidates for PCI.&#xD;
&#xD;
          2. Any of the target lesions meets any of the following criteria:&#xD;
&#xD;
               1. Aorto-ostial location (within 3 mm)&#xD;
&#xD;
               2. Lesion located in left main coronary artery&#xD;
&#xD;
               3. Lesion located within 2 mm of origin of the LAD or LCx&#xD;
&#xD;
               4. Lesion that involves a bifurcation with a side branch ≥ 2mm in diameter and&#xD;
                  ostial lesion &gt; 40% stenosed by visual estimation or side branch requiring&#xD;
                  intervention&#xD;
&#xD;
               5. Total occlusion (TIMI Flow 0), prior to wire crossing&#xD;
&#xD;
               6. Extreme tortuosity proximal to or within the lesion&#xD;
&#xD;
               7. Lesions having heavy calcification&#xD;
&#xD;
               8. Extreme angulation (≥ 90 %) proximal to or within the lesion&#xD;
&#xD;
          3. Evidence of previous revascularization:&#xD;
&#xD;
               1. Previous PCI with or without restenosis from previous intervention&#xD;
&#xD;
               2. Arterial or venous graft with or without lesion located within the graft or&#xD;
                  distal to a diseased arterial or saphenous vein graft&#xD;
&#xD;
          4. The target vessel contains visible thrombus.&#xD;
&#xD;
          5. Another (clinically significant or potentially significant) lesion left untreated&#xD;
             within target vessels (including side branch) or another significant vessel.&#xD;
&#xD;
          6. Subject requiring or potentially requiring interventional procedures other than&#xD;
             pre-dilatation and study device implantation and post dilatation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Alexandre Abizaid</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dante Pazzanese Hospital, Sao Paulo, Brazil</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Dante Pazzanese de Cardiologia</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>04012-909</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medistra Hospital</name>
      <address>
        <city>Jakarta</city>
        <zip>12950</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinic of Cardiology</name>
      <address>
        <city>Skopje</city>
        <zip>1000</zip>
        <country>Macedonia, The Former Yugoslav Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jantung Negara</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50400</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Indonesia</country>
    <country>Macedonia, The Former Yugoslav Republic of</country>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>December 7, 2015</study_first_submitted>
  <study_first_submitted_qc>January 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2016</study_first_posted>
  <last_update_submitted>August 16, 2018</last_update_submitted>
  <last_update_submitted_qc>August 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>MeRes-1 Extend</keyword>
  <keyword>MeRes100</keyword>
  <keyword>Sirolimus Eluting Bioresorbable Vascular Scaffold System</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

